Galapagos Reports Q1 Profit Turnaround, Details Major Gilead/Ouro Biotherapeutics Collaboration, and Strategic Pipeline Expansion

summarizeSummary

Galapagos NV reported a significant return to net profit in Q1 2026 and provided extensive details on its transformational collaboration with Gilead to acquire Ouro Medicines, adding a promising clinical-stage T cell engager and expanding its strategic R&D flexibility.

check_boxKey Events

• Q1 2026 Financial Turnaround

  Galapagos reported a net profit of €14.5 million for Q1 2026, a significant improvement from a net loss of €153.4 million in Q1 2025. The operating loss also substantially decreased to €63.7 million from €158.7 million year-over-year.

• Transformational Ouro Medicines Collaboration

  The company detailed its binding agreement with Gilead Sciences for Gilead's acquisition of Ouro Medicines, with Galapagos assuming Ouro's operating assets and personnel. Galapagos and Gilead will equally split the $1.675 billion upfront payment and up to $500 million in contingent milestone payments.

• Key Pipeline Asset Acquired: Gamgertamig

  The collaboration brings gamgertamig (OM336), a clinical-stage BCMAxCD3 T cell engager for autoimmune diseases, into Galapagos' pipeline. It has received Fast Track and Orphan Drug Designation from the U.S. FDA and is expected to enter registrational studies as early as 2027.

• Enhanced Strategic Flexibility and Capital Allocation

  The existing collaboration terms with Gilead will be amended to designate $500 million of Galapagos' cash for independent R&D or strategic transactions outside Gilead partnerships, including up to $150 million for potential share repurchases.

auto_awesomeAnalysis

This filing details a significant strategic pivot for Galapagos NV, marked by a return to net profitability in Q1 2026 and a transformational collaboration with Gilead to acquire Ouro Medicines. The acquisition of Ouro's clinical-stage T cell engager, gamgertamig, represents a substantial pipeline boost with Fast Track and Orphan Drug designations, positioning it for registrational studies as early as 2027. The deal also provides Galapagos with enhanced strategic flexibility, including a dedicated $500 million for independent R&D and business development, with a portion allocated for potential share repurchases. While year-end cash guidance is reduced due to the Ouro investment, the overall strategic direction and strengthened pipeline are highly positive for the company's long-term outlook.